⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1998922 | 0.92 | — | — | |
| SCHEMBL27056 | 0.87 | — | — | |
| Magnesium Chloride Anhydrous SCHEMBL27569410 | 0.77 | — | — | |
| SCHEMBL28846893 | 0.77 | — | — | |
| SCHEMBL136516 | 0.77 | — | — | |
| SCHEMBL13330134 | 0.77 | — | — | |
| SCHEMBL22109525 | 0.77 | — | — | |
| SCHEMBL16964880 | 0.71 | CYP1A2 (0.31) | — | |
| N-Methyl Pyrrolidine (Nmp) SCHEMBL37881 | 0.69 | — | — | |
| SCHEMBL10211088 | 0.69 | TDP1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024145505-A1 | PYRIMIDINE CARBOXAMIDE COMPOUNDS | ACRIVON THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | claimed |
| WO-2024145505-A1 | PYRIMIDINE CARBOXAMIDE COMPOUNDS | ACRIVON THERAPEUTICS, INC. (US) | 2024-07-04 | — | — | WO | disclosed |
| EP-3634953-B1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2024-01-03 | — | — | EP | disclosed |
| EP-4151627-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2023-03-22 | — | — | EP | disclosed |
| US-20220251098-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2022-08-11 | — | — | US | disclosed |
| US-20200165256-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2020-05-28 | — | — | US | disclosed |
| CN-111065626-A | Compounds for the treatment of huntington's chorea | PTC医疗公司 | 2020-04-24 | — | — | CN | disclosed |
| EP-3634953-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| WO-2018226622-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. (US) | 2018-12-13 | — | — | WO | disclosed |
| WO-2018103058-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE | JANSSEN PHARMACEUTICA NV (BE) | 2018-06-14 | — | — | WO | disclosed |
| EP-0222191-A1 | 4-Benzyl-1-2(H)-phthalazinone derivatives | ASTA Pharma AG (DE) | 1987-05-20 | — | — | EP | disclosed |
| EP-0174464-A2 | Substituted benzyl phthalazinone derivatives | ASTA Pharma AG (DE) | 1986-03-19 | — | — | EP | disclosed |
| US-4508732-A | Basic ethers useful as antidepressant agents | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1985-04-02 | — | — | US | disclosed |
| EP-0031885-B1 | BASIC ETHERS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND PROCESS FOR THEIR PREPARATION | MERCK PATENT GmbH (DE) | 1984-06-27 | — | — | EP | disclosed |
| US-4376123-A | Hexahydroazepinyloxy-chromones useful as antidepressants | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1983-03-08 | — | — | US | disclosed |
| US-4353913-A | ANTHELMINTICS | BAYER AKTIENGESELLSCHAFT (DE) | 1982-10-12 | — | — | US | disclosed |
| EP-0010242-B1 | BENZIMIDAZOLYL-2-CARBAMIC ACID ESTERS, MEDICAMENTS BASED THEREON AND PROCESS FOR THEIR PREPARATION | BAYER AG (DE) | 1982-09-29 | — | — | EP | disclosed |
| US-4287199-A | USEFUL AS ANTHELMINITICS | BAYER AKTIENGESELLSCHAFT (DE) | 1981-09-01 | — | — | US | disclosed |
| EP-0031885-A1 | Basic ethers, pharmaceutical compositions containing them and process for their preparation | MERCK PATENT GmbH (DE) | 1981-07-15 | — | — | EP | disclosed |
| EP-0010242-A1 | Benzimidazolyl-2-carbamic acid esters, medicaments based thereon and process for their preparation | BAYER AG (DE) | 1980-04-30 | — | — | EP | disclosed |